Thymoquinone ameliorates delayed cerebral injury and cerebral vasospasm secondary to experimental subarachnoid haemorrhage by Akkaya, Enes et al.
576 www.journals.viamedica.pl/neurologia_neurochirurgia_polska
Neurologia i Neurochirurgia Polska
Polish Journal of Neurology and Neurosurgery
2020, Volume 54, no. 6, pages: 576–584
DOI: 10.5603/PJNNS.a2020.0090
Copyright © 2020 Polish Neurological Society 
ISSN 0028–3843
RESEARCH PAPER
Address for correspondence: Enes Akkaya, Neurosurgery Department of Şişli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey,  
e-mail: drenesnrs@gmail.com
Thymoquinone ameliorates delayed cerebral injury and cerebral 
vasospasm secondary to experimental subarachnoid haemorrhage
Enes Akkaya1, Şevket Evran2, Fatih Çaliş3, Serdar Çevik4,5, Salim Katar6, Ersin Karataş7,  
Abdurrahim Koçyiğit7, Mustafa Yasin Sağlam8, Mustafa Aziz Hatiboğlu7, Hakan Hanimoğlu9,  
Mehmet Yaşar Kaynar10
1Neurosurgery Department of Şişli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey 
2Department of Neurosurgery, Haseki Training and Research Hospital, Istanbul, Turkey 
3Department of Neurosurgery, Medeniyet University, Goztepe Training and Research Hospital, Istanbul, Turkey 
4Department of Neurosurgery, Memorial Şişli Hospital, Istanbul, Turkey 
5Department of Physical Therapy and Rehabilitation, School of Health Sciences, Gelisim Universty, Istanbul, Turkey 
6Department of Neurosurgery, Faculty of Medicine, Balikesir University, Balikesir, Turkey 
7Bezmialem Vakif University School of Medicine, Istanbul, Turkey 
8Department of Pathology, Kartal Dr. Lütfi Kirdar Education and Training Hospital, Istanbul, Turkey 
9Biruni University Hospital, Istanbul, Turkey 
10Department of Neurosurgery, Cerrahpasa Faculty of Medicine, Istanbul, Turkey
ABSTRACT
Aim of the study. Among subarachnoid haemorrhage (SAH) patients, delayed cerebral injury (DCI) and infarction are the most 
important causes of death and major disability. Cerebral vasospasm (cVS) and DCI remain the major cause of death and disability. 
Thymoquinone (TQ) is the substance most responsible for the biological activity of nigella sativa (NS) and is useful in the treatment 
of ischaemic and neurodegenerative diseases, oxidative stress, inflammatory events, cardiovascular and neurological diseases. 
We conducted an experimental study aimed to investigate the preventive and corrective effects of TQ.
Materials and methods. 24 Sprague-Dawley rats were randomly divided into three groups. The first was the control group 
which was a sham surgery group. The second group was the SAH group where the double haemorrage SAH protocol was used 
to induce vasospasm. The third group was the SAH+TQ group, where cVS was induced by the SAH protocol and the animals recei-
ved oral 2 cc thymoquinone solution for seven days at a dose of 10 mg/kg, after the induction of SAH. The rats were euthanised 
seven days after the first procedure. The degree of cerebral vasospasm was evaluated by measuring the basilar artery luminal 
area and arterial wall thickness. Apoptosis was measured by the western blot method at brainstem neural tissue. Oxidative stress 
was measured by the Erel Method. Endothelin-1 was measured with ELISA analysis at blood. Statistical analysis was performed. 
Results. Endothelin-1 values were found to be statistically significantly lower in the control and SAH+TQ groups compared to 
the SAH group (P < 0.001). Mean lumen area values were significantly higher in the control and SAH+TQ groups than in the SAH 
group (P < 0.001). In the control and SAH+TQ groups, wall thickness values decreased significantly compared to the SAH group 
(P < 0.001). OSI values were significantly lower in the control and SAH+TQ groups than in the SAH group (P < 0.001). Apoptosis 
was significantly lower in the control and SAH+TQ groups than in the SAH group (P < 0.001).
Conclusion. Our results show that post-SAH TQ inhibits/improves DCI and cVS with positive effects on oxidative stress, 
apoptosis, ET-1, lumen area, and vessel wall thickness, probably due to its anti-ischaemic, antispasmodic, antioxidant, anti-
-inflammatory, anti-apoptotic and neuroprotective effects. 
Key words: aneurysm, thymoquinone, oxidative stress, subarachnoid haemorrhage, cerebral vasospasm, delayed cerebral injury
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Introduction
Among subarachnoid haemorrhage (SAH) patients, 
delayed cerebral injury (DCI) and infarction are the most 
important causes of death and major disability [1]. The major 
cause of DCI is cerebral vasospasm (cVS) [1, 2]. The prevention 
and treatment of DCI due to vasospasm developing after SAH 
have been key targets. Despite surgical and endovascular de-
velopments over the last 30 years, and improved intensive care 
unit (ICU) support, cVS and secondary DCI remain the major 
cause of death and disability [3]. Because cVS can develop due 
to many reasons and has a complex mechanism, many studies 
regarding its treatment have not achieved full success [4].
Nigella sativa (NS) is a plant common in Mediterranean 
countries and the Indian subcontinent. Studies have shown 
that thymoquinone (TQ) is the substance most responsible for 
the biological activity of this plant (30–48%) [5]. TQ is useful 
in the treatment of ischaemic and neurodegenerative diseas-
es, oxidative stress, inflammatory events, cardiovascular and 
neurological diseases [6–11]. TQ has attracted the interest of 
researchers into various diseases due to its antispasmodic, anti-
convulsant, antioxidant, and anti-inflammatory effects [12–14].
We conducted an experimental study designed to inves-
tigate the preventive and corrective effects of TQ molecule 
with antispasmodic, antioxidant, anti-inflammatory, and 
neuroprotective properties in DCI and cVS, which is the most 
important cause of DCI.
Clinical rationale for study
As doctors, we are still often helpless when faced with 
patients who develop CVS and DCI after SAH. While some 
of these patients survive although requiring long-term treat-
ment, many of them die. TQ is a natural molecule with proven 
positive effects and no noted side effects. Although the patho-
genesis of cVS and DCI is still not fully understood, certain 
pathways and markers have been identified. In this study, we 
showed that TQ improves these pathways and markers. In 
addition, we believe it might represent a potential cure for 
this disease.
Materıal and methods
We randomly divided 24 Sprague-Dawley rats (285–370 g, 
adults, males) into three groups. The first was the control group 
(n = 8), in which we did not induce aSAH or treatment, and 
only delivered oral saline by oral gavage. In this group, we 
punctured the cisterna magna as detailed below and slowly 
drained 0.1 mL CSF before injecting back into the cisterna 
magna after the induction of anaesthesia. We then delivered 
2 cc saline by oral gavage for seven days. 
The second group was the SAH group (n = 8). Here we 
used the SAH method to produce vasospasm, as detailed below. 
We then delivered 2 cc saline by oral gavage for seven days. 
The third and final group was the SAH+TQ group (n = 8), 
where we used SAH method and gave an oral 2 cc thymoqui-
none (Sigma-Aldrich (St. Louis, MO, USA)) solution for seven 
days at a dose of 10 mg/kg to animals after the induction of 
SAH. We chose this dose according to a previous study [15]. 
We kept the animals at a temperature of 22°C (± 2°C) and 
gave them a normal diet, implementing a 12-hour light/12-
hour dark cycle. We gave 5 mL of lactated ringer’s to animals 
intraperitoneally after the procedure. They had free access to 
water. All the rats breathed spontaneously during the opera-
tions. We sedated animals using a combination of intramuscu-
lar administration of 60 mg/kg ketamine hydrochloride (Parke 
Davis, Istanbul, Turkey) and 5 mg/kg xylazine hydrochloride 
[Rompun 2% solution, 50 cc bottle (Bayer-Türk Ilaç Ltd., 
Istanbul, Turkey)].
We maintained animal welfare, and all processes were in 
accordance with the European Communities Council Directive 
of 24 November, 1986 (86/609/EEC) concerning the protection 
of animals for experimental use. All experimental procedures 
used in this investigation were reviewed and approved by the 
ethical committee of Bezmialem University.
Double haemorrhage model for cVS 
We chose this method because of its high effectiveness 
compared to other models [16]. Firstly, we placed rats in 
the supine position and catheterised tail arteries for fresh 
arterial blood. Then we placed rats in the prone position. We 
made a midline nuchal incision, and dissected cutaneous and 
subcutaneous tissues, fascia and muscular tissues to approach 
to atlanto-occipital membrane. We inserted a 25-G injector 
into the cisterna magna, removed 0.1 mL of CSF, and injected 
0.1 mL of fresh, non-heparinised autologous arterial blood 
obtained from the tail artery, aseptically into the cisterna 
magna within a maximum of two minutes. We sealed the 
puncture site with glue after the blood injection. We tilted 
all rats, heads lowered at an angle of 30°, for 30 minutes to 
allow blood deposition among basal cisterns. We left the rats 
in separate cages after recovery from anaesthesia and rou-
tinely checked their vital signs. We repeated the same routine 
after 48 hours. We gave animals thymoquinone solution by 
oral gavage for seven days, but only to the SAH+TQ group. 
During our experiment, five rats died and were excluded. 
Four of these were in the SAH group and the other was in 
the SAH+TQ group. We introduced new rats to the groups 
to replace them. 
Euthanisation
Seven days after the first procedure, after sedating animals, 
we took blood samples (10 cm3 ) from the left ventricle for 
biochemical examination, and euthanised rats by beheading 
them. After that, we removed the brainstems carefully and 
preserved them in a 10% formaldehyde solution for 24 hours. 
We divided these tissues into two parts for pathological ex-
amination and biochemical analysis. We centrifuged blood 
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samples at 1,000 g for five minutes, and took upper clear 
supernatants for examination. We stored all serum samples 
at −80°C until analysed.
Histologic morphometric analysis  
of the basilar artery
We evaluated the severity of cerebral vasospasm by 
evaluating the basilar artery luminal area and arterial wall 
thickness. The basilar artery sections were deparaffinised, 
hydrated, washed, and stained with H & E Basilar arteries. 
10 mm thick section micrographs were analysed using Im-
ageJ version 1.45 (NIH). We calculated cross-sectional areas 
from the perimeter of the luminal border. We measured, and 
averaged for each vessel, three continuous sections (i.e. mid-
point of proximal, middle, distal). The staining results were 
evaluated at 400× magnification by two blinded investigators 
with no knowledge of the treatment groups. The mean ± SEM 
value obtained for each artery was used as the final value for 
a particular vessel. 
Biochemical analysis
Western blot method
Tissues obtained from animals were homogenised with 
metal beads in RIPA buffer (0.5M Tris-HCl, pH 7.4, 1.5M 
NaCl, 2.5% deoxycholic acid, 10% NP-40, 10mM EDTA). 
Homogenised tissues were centriged at 14,000 rpm for 10 min-
utes at 4°C. Supernatants were collected to use as protein 
samples, and stored at −20°C until experiments begin. The 
Bradford method was used to measure protein amount of the 
samples [17]. Samples were loaded to SDS polyacrylamide 
gel of 12% to ensure 80μg in each well. Electrophoresis was 
performed to allow the gel 80 V for 20 minutes and 120 V 
for 100 minutes. After electrophoresis, gels were transferred 
to the PVDF (polyvinylidene fluoride) membrane using an 
IBlot (Thermo Fisher, Waltham, MA, USA) device. These 
processes were repeated for each antibody. Bax (1:1,000 dilu-
tion, NB110-55492, Novus Biologicals, Centennial, CO, USA) 
Bcl-2 (1:1,000 dilution NB100-92142, Novus Biologicals), 
Active Caspase-3 (1:1,000 dilution, NB100-56113 Novus Bi-
ologicals) and ß-Actin (1:1,000 dilution, NBP1-47423 Novus 
Biologicals) antibodies were used in our study. Membranes 
were visualised with a western blotting luminol reagent 
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) solution 
for chemiluminescence imaging after treatment with each 
antibody. Imaging was performed via the Vilber Laurmat 
Fx5 Fusion (Vilber, Paris, France) imaging system. Image J 
(Glyko, Novato, CA, USA) software was used for analysis of 
the obtained images in optic density. 
Oxidative stress analysis
Total antioxidant status (TAS; mmol trolox equiv/L) 
and total oxidant status [TOS; (μmol H2O2 equiv/L)] were 
determined using commercially available kits (Rel Assay 
Diagnostics; Mega Tip, Gaziantep, Turkey). The oxidative 
stress index [OSI; OSI (AU) = TOS (mmol H2O2 equiv/L)/
TAS (mmol trolox equiv/L)] was calculated. Serum TAS and 
TOS levels were determined via the colorimetrical method 
using a Varioskan Flash Multimode Reader (Thermo Fisher) 
and measurement methods developed by Erel [18, 19].
ELISA analysis
Tissue samples were thawed, and an Enzyme-Linked Im-
munoSorbent Assay (ELISA) kit was used for the quantitative 
measurement of endothelin-1. The ELISA was performed 
according to the manufacturer’s instructions (Sunlong SL-
0252Ra, China). Optical density was read on a standard au-
tomated plate reader at 450 nm (Bio-Rad, iMark Microplate 
Absorbance Reader).
Statistical analysis
We defined quantitative variable behaviour using meas-
ures of centralisation and variation as mean ± SD. We used 
a one-way analysis of variance F test to show the differences 
in behaviour of the group means in cases where assumptions 
such as independence, normality, and homoscedasticity 
was met. We conducted Tukey post hoc analysis for multi-
ple comparisons. We established statistical significance as   
P = 0.05 for all cases. A GraphPad Prism Version 6 Software 
Program (GraphPad Software, San Diego, CA, USA) was used 
to achieve statistical analyses.
Results
When the apoptotic proteins Caspase-3 and Bax proteins 
were examined, they were found to be highest in the SAH 
group and lowest in the control group (Tab. 1). Caspase-3 val-
ues were significantly lower in the control group (P < 0.001) 
and in the SAH+TQ group (P < 0.01) compared to the 
SAH group (Fig. 1C). Bax protein was significantly lower 
in the control and SAH+TQ groups than in the SAH group 
(P < 0.001) There was no statistically significant difference 
between the SAH+TQ group and the control group for both 
parameters (P > 0.05) (Fig. 1A, C).
Bcl-2, an anti-apoptotic protein, was found to be the lowest 
in the SAH group and the highest in the control group (Tab. 
1). Bcl-2 values in the SAH+TQ and control groups were 
significantly higher than in the SAH group (P < 0.001). There 
was no statistically significant difference between the SAH+TQ 
group and the control group (P < 0.05) (Fig. 1B).
According to our results, endothelin-1 values were found 
to be the lowest in the control group, and the highest in the 
SAH group (Tab. 1). Endothelin-1 values were found to be 
statistically significantly lower in the control and SAH+TQ 
groups compared to the SAH group (P < 0.001). There was no 
statistically significant difference between the SAH+TQ group 
and the control group (P > 0.05) (Fig. 2A).
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Table 1. Mean values and standard deviations of parameters 
PARAMETER CONTROL GP SAH GP TREATMENT GP P value
Endothelin-1 [ng/L] 33.19 ± 2.311 74.91 ± 2.914 41.01 ± 1.064 < 0.001
Luminal area 0.1388 ± 0.002266 0.0975 ± 0.003134 0.1313 ± 0.003981 < 0.001
Wall thickness 0.0225 ± 0.001637 0.03375 ± 0.001830 0.02313 ± 0.001619 < 0.001
TAS [Trolox equivalent/L] 1.901 ± 0.05300 0.7463 ± 0.08512 1.733 ± 0.0375 < 0.001
TOS [µmol H2O2 Eqv./L] 8.029 ± 0.2033 13.33 ± 0.3248 9.760 ± 0.3439 < 0.001
OSI [arbitrary unit] 425.2 ± 18.05 1,969 ± 238.7 564.9 ± 20.01 < 0.001
Bcl-2/β-actin 1.883 ± 0.05135 0.3591 ± 0.04956 1.558 ± 0.1136 < 0.01
Caspase-3/β-actin 0.3948 ± 0.08323 1.691 ± 0.1912 0.6946 ± 0.1166 < 0.001
Bax/β-actin 0.4173 ± 0.06607 1.864 ± 0.1943 0.7719 ± 0.06448 < 0.001
Figure 1. A. BAX (P < 0.001) comparing SAH group to control group and SAH+TQ group, *P > 0.05 and comparing control group to SAH+TQ 
group; B. BCL-2 (P < 0.001) comparing SAH group to control group and SAH+TQ group, **P < 0.05 comparing control group to SAH+TQ 
group; C. Caspase-3 (P < 0.01) comparing SAH group to SAH+TQ group, ++++P < 0.001 comparing SAH group to control group, *P > 0.05 
comparing control group to SAH+TQ group
Figure 2. A. Endothelin-1 (P < 0.001) comparing SAH to control and SAH+TQ groups, *P > 0.05 comparing control group to SAH+TQ group; 
B. Lumen area (P < 0.001) comparing SAH group to control and SAH+TQ groups, *P > 0.05 comparing control group to SAH+TQ group; 
C. Wall thickness (P < 0.001) comparing SAH to control and SAH+TQ groups, *P > 0.05 comparing control group to SAH+TQ group
When we look at the luminal area measurements, the 
luminal area which is the lowest value in the SAH group 
compared to the others was found to be the highest level in 
the control group compared to the others (Tab. 1). Mean lu-
men area values were significantly higher in the control and 
SAH+TQ groups than in the SAH group (P < 0.001). There 
was no statistically significant difference between the SAH+TQ 
and control groups (P > 0.05) (Fig. 2B).
The mean basilar artery wall thickness was the highest in 
the SAH group, and the lowest in the control group (Tab. 1). 
In the control and SAH+TQ groups, wall thickness values de-
creased significantly compared to the SAH group (P < 0.001). 
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Figure 3. A. TAS (P < 0.001) comparing SAH group to control and SAH+TQ groups, *P > 0.05 comparing control group to SAH+TQ group; B. 
TOS (P < 0.001) comparing SAH group to control and SAH+TQ groups, **P < 0.05 comparing control group to SAH+TQ group; C. OSI (P < 
0.001) comparing SAH group to control and SAH+TQ groups, *P > 0.05 comparing control group to SAH+TQ group
There was no statistically significant difference between the 
SAH+TQ and control groups (P > 0.05) (Fig. 2C).
The TOS and OSI values, which showed oxidative stress, 
reached the highest values in the SAH group compared to the 
other groups, and remained at the lowest levels in the control 
group. TAS values showing antioxidant activity were highest 
in the control group and lowest in the SAH group (Tab. 1). 
TAS values in the control and SAH+TQ groups increased 
significantly (P < 0.001) compared to the SAH group, and 
there was no statistically significant difference between the 
SAH+TQ group and the control group (P > 0.05) (Fig. 3A). 
TOS and OSI values were significantly lower in the control 
and SAH+TQ groups than in the SAH group (P < 0.001) (Fig. 
3B, C). There was no statistically significant difference in TOS 
values between the SAH+TQ and control groups (P < 0.05) 
(Fig. 3B). In terms of OSI values, there was no statistically sig-
nificant difference between the SAH+TQ and control groups 
(P > 0.05) (Fig. 3C).
Dıscussıon
We evaluated TQ for the first time in cerebral vasospasm 
and delayed cerebral injury for the prevention and treatment 
in a rat double haemorrhage study, which is considered to be 
the most effective method for experimental vasospasm [16]. 
The results showed that the lumen area was enlarged and the 
wall thickness and ET-1 levels were decreased in the TQ group, 
which are cVS markers. This indicates that the severity of cVS 
decreased after TQ treatment. Also, apoptosis and oxidative 
stress, the markers of DCI following cVS, were significantly 
reduced in the TQ-treated groups. Although these positive 
changes in the results did not reach normal values in the 
control group, improvements were observed at a high level 
of significance.
Vasospasm-associated infarcts occur in 20–50% of patients 
with SAH, and severe morbidity in 30–40% [20−22]. DCI is 
thought to develop due to cVS and arterial contraction [23, 
24]. In the chronic phase, cVS and DCI are the main culprits 
for poor progress. DCI is responsible for a poor outcome or 
death in 30% of those treated adequately after aneurysmal 
SAK [25, 26]. This has been associated with many reasons, 
with endothelial damage, proinflammatory processes, and 
cVS-induced CBF reduction being the most important ones 
[27]. To the best of our knowledge, TQ has positive effects in 
preventing endothelial and ischaemic damage, and in reducing 
inflammation [5, 28−33]. Similar to DCI, oxidative stress, 
inflammatory pathways, electrolyte changes, and apoptosis, 
which are responsible for the pathophysiology of cVS, play an 
important role [22, 23]. Preventive and corrective effects of TQ 
against oxidative stress and apoptosis have been demonstrated 
[5, 8, 34]. According to our results, TQ prevented and regressed 
many factors that play a role here.
Recently, the goal of treatment in SAH patients has been 
to avoid DCI by preventing cVS and to improve clinical out-
comes. Therapy modalities that target not only cVS but also 
DCI are more effective. cVS,  those secondary to cVS (DCI, 
apoptosis, oxidative stress), and the causes of cVS (oxidative 
stress, ET-1, early brain injury (EBI)) should be targeted. New 
molecules with anti-inflammatory, antioxidant, and antiapop-
totic properties are now in the spotlight, and studies with these 
molecules are promising [23]. TQ also seems to be a potential 
treatment modality because of these features.
TQ is the most efficient ingredient/molecule of nigella 
sativa (NS, black seed) in essential oil; most of the benefi-
cial properties of NS are attributable to this substance. Cell 
culture studies and animal models have demonstrated many 
therapeutic potentials of black seed and its active component, 
TQ, such as anti-inflammatory and antioxidant [11]. In some 
studies, TQ has shown the potential to improve the condition 
in many different types of autoimmune diseases [5]. The use of 
NS has been reported to be safe, with no adverse effects even 
at treatment doses [9, 11]. Anti-ischaemic properties [8] and 
the effects of improving endothelial dysfunction [7, 28] are im-
portant in preventing DCI and cVS developing after SAH. This 
is because endothelial dysfunction progresses to vasospasm, 
which causes ischaemia, and ischaemia also leads to DCI. TQ, 
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A B C
Figure 4. Cross-sectional microscopic image of basilar artery of control group (A), SAH group (B), and SAH+TQ group (C) at 400× magnification
Figure 5. Basal cisterns (A) and cisterna magna with blood clots (B)
A B
because of its antioxidant and neuroprotective properties, has 
the potential for the treatment of these pathological events 
involved in the pathogenesis of cVS and DCI. In a study similar 
to the ischaemia pattern in cVS, neuroprotective properties 
of NS were examined and positive effects were detected in 
MCA-occluded rats, and also neuroprotective properties were 
prominent in other studies [6, 35−37]. Since ischaemia and 
infarcts due to cVS after SAH are caused by a similar mecha-
nism, it is feasible that TQ will have the same effect. 
Similarly, in our study, we started TQ immediately after 
the first haemorrhage, in other words before the development 
of cVS and DCI. We did not evaluate these substrates and 
enzymes in our study, but these effects may be the reason why 
oxidative stress falls in the treatment group.
Vasospasm is an elongated arterial constriction caused 
by the contraction of vascular smooth muscles [24]. SAH 
causes endothelial disruption and reduces susceptibility to 
vasodilation response by reducing nitric oxide and prosta-
glandin-I2 production from the endothelium [3]. Substances 
released from the endothelium govern events such as vascular 
tone adjustment, smooth muscle cell proliferation, and throm-
bosis [1, 38]. TQ has the effect of dilating the pulmonary, 
aortae, mesenteric, and coronary arteries. It has been shown to 
relax smooth muscle cells [7, 39, 40]. The antispasmodic effect 
has also been shown to block calcium channels. In this respect, 
it is similar to calcium channel antagonists and nimodipine 
which is the only agent accepted in some treatment guidelines. 
In our results, the luminal area was significantly increased 
and the wall thickness was significantly decreased in the 
TQ-treated group compared to the SAH group. Since TQ was 
given from the first day of bleeding, we can deduce from these 
results that TQ is a successful agent in preventing/regressing 
SAH-related cVS.
Endothelin-1 (ET-1) has the strongest role in vasocon-
striction. ET-1 is more specific for cerebral circulation and 
stimulates smooth muscle cell proliferation, fibrosis, and 
inflammation. It is secreted from endothelial cells [24]. En-
dothelial alterations in ET-1 metabolism are thought to play 
an important role in the pathogenesis of cVS. Serum and 
plasma ET-1 levels increase after minutes of SAH. Therefore, 
ET-1 is a reliable marker for the prognosis of cVS after SAH 
and a potent marker for radiological cVS monitoring [23, 
41]. We also compared ET-1 levels to assess the effect of TQ 
on cVS; ET-1 levels were significantly decreased in the TQ 
group compared to the SAH group. Based on this, we think 
that the severity of cVS decreases due to TQ. Already the other 
indicators of cVS, luminal area and wall thickness, are also 
correlated with ET-1 results.
Oxidative stress plays a crucial role in EBI and triggers 
many events leading to DCI. There is also oxidative damage at 
the end of the DCI process. This correlates with the severity of 
DCI. Oxidative damage is both the cause and consequence of 
cVS and DCI. Immediately after SAH, reactive oxygen species 
(ROS) are produced from clots and the enzymes of the anti-
oxidant defence systems are quickly depleted. Oxidative stress 
triggers many events such as endothelial damage and dysfunc-
tion, smooth muscle proliferation, activation of inflammation 
cascades, and production of locally potent vasoconstrictors. 
Because it starts to have an effect early on, treatment is very 
difficult in that period [23]. Various free radical scavengers 
have been tried to prevent cVS, but they have not been entirely 
successful [42]. In our results, when the oxidative stress index 
increased significantly in the SAH group, it decreased signifi-
cantly with TQ administration. Accordingly, we argue that TQ 
prevents/reduces oxidative stress. Similar effects have previously 
been identified in other studies [5, 8, 10, 11, 38].
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Secondary brain injury is mainly caused by apoptosis. Cell 
death begins with the activation of caspases within 24 hours 
after SAH [23, 43]. Oxidative stress and ischaemia trigger 
apoptosis [41]. TQ may prevent apoptosis by both reducing 
oxidative stress molecules and maintaining the width of the 
vessel lumen diameter. It is also known that TQ inhibits apop-
tosis directly through caspase pathways [6, 34, 44]. 
We can say that TQ reduces apoptosis due to SAH, hypop-
erfusion and oxidation by decreasing caspase and Bax levels 
and increasing BCl-2 levels. We observed that when apoptosis 
levels were very high in the SAH group, they decreased sig-
nificantly after TQ was administered. Thus, we conclude that 
TQ inhibits cVS and DCI which cause apoptosis and directly 
inhibits apoptosis. Bax values decreased in the TQ treatment 
group at a P < 0.001 significance level, while caspase-3 values 
decreased at a P < 0.01 significance level. 
It can be concluded that TQ inhibits Bax-induced apoptot-
ic pathways more than caspase-3 dependent pathways. Overall, 
we can talk about the positive effect of TQ because apoptosis 
values decreased significantly.
TQ also has effects that regulate blood pressure. In cases 
of hypertension involved in the treatment of cVS, it may have 
a negative effect on vasospasm treatment due to its effect of 
slightly reducing blood pressure. There will be deterioration 
of brain perfusion due to decreased blood pressure. However, 
due to its effects such as preventing endothelial damage and 
reducing vasospasm, these potentially negative effects have not 
been reflected in our experience. We have not used a method 
of measuring brain perfusion directly, but we can see indirect 
findings suggesting that brain perfusion is intact.
Several studies have shown that thrombosis in the sub-
arachnoid space leads to inflammation which plays a major 
role in cVS [24, 41, 45]. TQ may also prevent cVS because 
it inhibits inflammation in many ways [5, 9−11, 30, 31]. We 
did not look at the parameter of inflammation, but we can 
assume this because it ultimately prevents cVS, and we intend 
to evaluate it in future studies.
Cognitive dysfunction is frequently experienced after 
SAH. There are many neurocognitive positive effects of TQ, 
but as far as we know no research has been conducted to 
evaluate this. Perhaps. in future animal and clinical studies, 
this parameter could be examined [6, 11].
Clinical implıcatıons/future directions 
When we look at these results, it is difficult to under-
stand the mechanism by which TQ makes the effects we 
have identified. However, it has well-known anti-ischaemic, 
antispasmodic, antioxidant, anti-inflammatory, anti-apoptotic 
and neuroprotective effects. Probably due to these effects, we 
found that the biochemical and histopathological parameters 
of cVS and DCI were improved. 
Our results show that post-SAH TQ inhibits/improves DCI 
and cVS with positive effects on oxidative stress, apoptosis, 
ET-1, lumen area, and vessel wall thickness. Using this mol-
ecule, we propose conducting a large group clinical study in 
cVS and DCI after SAH.
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